Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q1 2026 Earnings Conference Call. [Operator ...
On a non-GAAP basis, total operating expenses decreased by 13% relative to the prior year, attributed primarily to lower ...
"We continue to make good progress in the first quarter of 2026 as we advance towards multiple important milestones for ZYNLONTA over the remainder of the year, beginning with the expected LOTIS-5 top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results